Literature DB >> 27173243

Molecular analysis of MLH1 variants in Chinese sporadic colorectal cancer patients.

H X Peng1,2, X Xu3, R Yang4, Y M Chu2, D M Yang2, Y Xu2, F L Zhou2, W Z Ma3, X J Zhang3, M Guan3, Z H Yang5, Z D Jin1.   

Abstract

Single nucleotide polymorphisms (SNPs) in mismatch repair genes, especially in the MLH1 gene, are closely associated with susceptibility to hereditary nonpolyposis colorectal cancer. However, few relevant findings are available regarding the association between sporadic colorectal cancer (SCRC) and SNPs of MLH1 in Chinese patients. Therefore, the present study aimed to describe the pathogenic association between three important MLH1 polymorphisms and SCRC in the Chinese population. Peripheral blood samples from 156 SCRC patients and 311 healthy controls were collected. DNA was purified from peripheral blood, and the V384D, R217C, and I219V polymorphisms were evaluated using high-resolution melting analysis and direct sequencing. The association between the three important MLH1 polymorphisms and clinical pathological features of the SCRC patients was analyzed. In addition, PMS2-MLH1 protein interactions were determined by co-immunoprecipitation (Co-IP) to determine the protein functional alteration induced by these SNPs. Among the three polymorphisms, V384D was significantly associated with the risk of SCRC (OR = 31.36, P < 0.0001). The allele frequencies were 4.81 and 0.16% in the SCRC group. No association was found between SCRC and R217C, or between SCRC and I219V. Moreover, the allele frequency of R217C was significantly higher in the SCRC patients younger than 60 years than in those older than 60 years. Co-IP showed that the MLH1 R217C, V384D, and I219V variants had relative binding abilities with PMS2 of 0.59, 0.70, and 0.80, respectively, compared with the wild-type. These findings suggest that MLH1 V384D could be a promising genetic marker for susceptibility to SCRC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27173243     DOI: 10.4238/gmr.15027689

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  6 in total

1.  A modifier of Huntington's disease onset at the MLH1 locus.

Authors:  Jong-Min Lee; Michael J Chao; Denise Harold; Kawther Abu Elneel; Tammy Gillis; Peter Holmans; Lesley Jones; Michael Orth; Richard H Myers; Seung Kwak; Vanessa C Wheeler; Marcy E MacDonald; James F Gusella
Journal:  Hum Mol Genet       Date:  2017-10-01       Impact factor: 6.150

2.  Pooling-analysis on hMLH1 polymorphisms and cancer risk: evidence based on 31,484 cancer cases and 45,494 cancer-free controls.

Authors:  Sha Li; Yi Zheng; Tian Tian; Meng Wang; Xinghan Liu; Kang Liu; Yajing Zhai; Cong Dai; Yujiao Deng; Shanli Li; Zhijun Dai; Jun Lu
Journal:  Oncotarget       Date:  2017-10-10

3.  Combinatorial approach of in silico and in vitro evaluation of MLH1 variant associated with Lynch syndrome like metastatic colorectal cancer.

Authors:  Komal Saleem; Tahir Zaib; Wei Ji; Chunhui Zhang; Qian Qin; Yusi Wang; Lidan Xu; Hanfei Yu; Siqi Zhu; Kexian Dong; Shuhan Si; Xueyuan Jia; Jie Wu; Songbin Fu; Wenjing Sun
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

4.  High prevalence of the MLH1 V384D germline mutation in patients with HER2-positive luminal B breast cancer.

Authors:  Seung Eun Lee; Hye Seung Lee; Kyoung-Yeon Kim; Jung-Hoon Park; Hanseong Roh; Ha Young Park; Wan-Seop Kim
Journal:  Sci Rep       Date:  2019-07-29       Impact factor: 4.379

5.  Isolated MLH1 Loss by Immunohistochemistry Because of Benign Germline MLH1 Polymorphisms.

Authors:  Dustin E Bosch; Matthew M Yeh; Stephen J Salipante; Angela Jacobson; Stacey A Cohen; Eric Q Konnick; Vera A Paulson
Journal:  JCO Precis Oncol       Date:  2022-08

6.  Analysis of the Circadian Regulation of Cancer Hallmarks by a Cross-Platform Study of Colorectal Cancer Time-Series Data Reveals an Association with Genes Involved in Huntington's Disease.

Authors:  Müge Yalçin; Rukeia El-Athman; Koliane Ouk; Josef Priller; Angela Relógio
Journal:  Cancers (Basel)       Date:  2020-04-13       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.